Printer Friendly

BARCOLENE/PENN CHAMP AND FOUNTAIN PHARMACEUTICALS TEAM UP FOR EXCITING NEW SUNTAN PROGRAM

 BARCOLENE/PENN CHAMP AND FOUNTAIN PHARMACEUTICALS
 TEAM UP FOR EXCITING NEW SUNTAN PROGRAM
 LARGO, Fla., March 23 /PRNewswire/ -- Barcolene/Penn Champ and Fountain Pharmaceuticals, Inc. (NASDAQ: FPHI) today jointly announced they have reached an agreement pursuant to which they will produce for a major department store chain a new "line extension" sun screen product.
 Barcolene/Penn Champ, Holbrook, Mass., the specialty chemicals division of Bissell, Inc., currently manufactures a full line of suntan products for, among others, a major national department store chain. This chain will add two new products to its private label line utilizing the Fountain "Lyphazome(TM)" brand liposomes for all-day protection. These additions are scheduled for the 1992 season and may debut as early as March.
 Bissell, Inc., a privately held multinational company has been in business since 1876. Diverse in business, Bissell, Inc. is comprised of three major divisions. The Home Care Division, of which Barcolene/Penn Champ is a part, manufactures consumer products ranging from floor care appliances to health and beauty care products. The Health Care Division and Graphics Division make up the balance of the company.
 A spokesperson for Fountain Pharmaceuticals, Inc. stated that an opening order from Barcolene/Penn Champ has already been received and filled. He further stated that although the opening order will produce only minimal revenues for the company, he was nonetheless excited at the opportunity created by the venture and looked forward to the success of this private label line extension product.
 Fountain Pharmaceuticals, Inc. is a development stage company specializing in the application of encapsulated drug delivery systems that improve drug compound delivery and enhance effectiveness of existing products. Fountain also develops proprietary products with applications in agricultural and consumer goods industries.
 /delval/
 -0- 3/23/92
 /CONTACT: Clark A. Marcus of Fountain Pharmaceuticals, 813-392-5300/
 (FPHI) CO: Barcolene/Penn Champ; Fountain Pharmaceuticals, Inc.; Bissell, Inc. ST: Florida, Massachusetts IN: MTC SU: JVN


MK-JS -- PH017 -- 0597 03/23/92 13:06 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 23, 1992
Words:325
Previous Article:DEFINITIVE ACQUISITION AGREEMENT SIGNED BETWEEN ROBERTS PHARMACEUTICALS AND NATIONAL CLINICAL RESEARCH CENTERS
Next Article:DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
Topics:


Related Articles
P&G SUES BARCOLENE TO STOP PATENT INFRINGEMENT
P&G SETTLES SHAMPOO INFRINGEMENT SUIT
Special alliance expands drug company's markets; in association with RBS.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters